Plasmodium falciparum dihydroorotate dehydrogenase (Pf DHODH) is an essential enzyme in the de novo pyrimidine biosynthesis pathway and a validated antimalarial drug target. Inhibition of Pf DHODH enzyme disrupts nucleotide synthesis, which leads to parasite death. Field-based 3D QSAR models were developed using a dataset of 75 Pf DHODH inhibitors to identify key features interacting with the active site of the enzyme. Partial least squares (PLS) analysis was performed, and contour-map interpretation guided the design of new 2-aminopyrido3, 4- d pyrimidin-4-one derivatives. The activity (pIC 50) values of designed compounds were predicted using the PLS model-5. Drug-likeness and pharmacokinetic profiles of the designed compounds were evaluated through in silico ADMET prediction study. Molecular docking studies were performed for the designed compounds using AutoDock Vina 1. 2. 7 with the Pf DHODH crystal structure. Further, the compound with the best docking score was evaluated for stability using 200 ns molecular dynamics simulations and MM/GBSA calculations with gmxMMPBSA tools. The 3D QSAR model exhibited good statistical reliability with R 2 of 0. 9 and Q 2 of 0. 805. The generated contour maps were used for the design of new 2-aminopyrido3, 4- d pyrimidin-4-one derivatives. These analogues showed moderate predictive activity (pIC 50) in the range of 7. 3–7. 741. In silico ADMET evaluation showed that the designed molecule has acceptable drug-likeness and pharmacokinetic profiles. Docking studies revealed that compound 2d showed the highest docking score (-9. 541 kcal/mol) and formed key interactions similar to those observed in the reference inhibitor DSM265 (-9. 326 kcal/mol). MD simulation studies confirmed that compound 2d showed good stability of the complex with Pf DHODH over the 200 ns trajectory and with MM/GBSA calculations. These results suggest that the designed compounds have the potential to act as Pf DHODH inhibitors and antimalarial agents. A novel series of 2-aminopyrido3, 4- d pyrimidin-4-one will be synthesized and further evaluated experimentally for Pf DHODH inhibition and antimalarial activity.
Bhatt et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: